Welcome to Chimerix
Chimerix discovers, develops and commercializes therapeutics with enhanced pharmaceutical properties that are active against a broad range of viral diseases. Leveraging a powerful lipid prodrug technology, ProLipTagTM, Chimerix is able to develop drug candidates with oral-availability, increased potency and targeted delivery. These enhanced pharmaceutical properties can be applied to new drug moieties or known drugs to improve dosing parameters, broaden therapeutic applications and decrease the risk of adverse reactions.
Technology Benefits
Leveraging a powerful lipid,
pro-drug technology Chimerix is able to develop drug candidates with improved oral-availability. [more]
Product Pipeline
Product pipeline developed based on the Chimerix technology ProLipTagTM [more]
Latest News
June 16, 2009
Developing a Broad Spectrum Antiviral Drug for the Treatment of Smallpox
7th annual Biodefense Vaccines & Therapeutics, June 15-17, 2009 Almas Temple Club, Washington, DC
[more]
May 19, 2009
Emergency IND granted for the use of CMX001 to treat complications following smallpox vaccination
[more]
Next Event
April 18, 2008 - Chimerix to present at 25th Annual Venture Conference
Chimerix company overview
[more]
June 10, 2008 - Chimerix to present at XVII International HIV Drug Resistance
Hexadecyloxypropyl tenofovir (CMX157) Has Enhanced Potency in Vitro against NRTI Resistant HIV Relative to Tenofovir and a Favorable Preclinical Profile
[more]
